Condensed Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 6,164,005	$ 9,968,600
Short-term investments available-for-sale, at fair value	27,613,031
Accounts receivable	3,361,333	6,356,268
Inventory, net of allowance of $39,403 at September 30, 2018 and $62,142 at December 31, 2017	1,129,092	1,180,521
Prepaid expenses and other	688,556	443,068
Total current assets	38,956,017	17,948,457
Restricted cash - non-current	3,270,247
Deferred offering costs		2,953
Deferred MidCap revolving loan costs	71,126
Property and equipment, net	2,614,620	3,304,890
Total assets	44,912,010	21,256,300
Current liabilities:
Accounts payable	1,867,181	2,438,798
Accrued liabilities	2,530,615	3,746,786
Contract liabilities - current	273,763	665,882
NuvoGen obligation - current	593,860	496,442
Growth Term Loan payable - net of discount and debt issuance costs		5,793,599
Other current liabilities	199,621	200,460
Total current liabilities	5,465,040	13,341,967
NuvoGen obligation - non-current, net of discount	6,684,631	7,520,913
Convertible note, related party - net of debt issuance costs	2,970,850	2,960,760
MidCap Term Loan payable - net of discount and debt issuance costs	6,666,796
Other non-current liabilities	333,367	492,197
Total liabilities	22,120,684	24,315,837
Commitments and Contingencies (Note 14)
Stockholders’ equity (deficit):
Common stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2018 and December 31, 2017, 28,479,341 shares issued and outstanding at September 30, 2018 and 13,929,763 shares issued and outstanding at December 31, 2017	28,479	13,929
Additional paid-in-capital	171,663,874	131,492,595
Accumulated other comprehensive loss	(8,882)
Accumulated deficit	(148,892,145)	(134,566,061)
Total stockholders’ equity (deficit)	22,791,326	(3,059,537)
Total liabilities and stockholders' equity (deficit)	$ 44,912,010	$ 21,256,300